Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Policies for biosimilar uptake in Europe: An overview.
Moorkens E, Vulto AG, Huys I, Dylst P, Godman B, Keuerleber S, Claus B, Dimitrova M, Petrova G, Sović-Brkičić L, Slabý J, Šebesta R, Laius O, Karr A, Beck M, Martikainen JE, Selke GW, Spillane S, McCullagh L, Trifirò G, Vella Bonanno P, Mack A, Fogele A, Viksna A, Władysiuk M, Mota-Filipe H, Meshkov D, Kalaba M, Mencej Bedrač S, Fürst J, Zara C, Skiöld P, Magnússon E, Simoens S. Moorkens E, et al. Among authors: viksna a. PLoS One. 2017 Dec 28;12(12):e0190147. doi: 10.1371/journal.pone.0190147. eCollection 2017. PLoS One. 2017. PMID: 29284064 Free PMC article.
The Expiry of Humira® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures.
Moorkens E, Godman B, Huys I, Hoxha I, Malaj A, Keuerleber S, Stockinger S, Mörtenhuber S, Dimitrova M, Tachkov K, Vončina L, Palčevski VV, Achniotou G, Slabý J, Popelková L, Kohoutová K, Bartels D, Laius O, Martikainen JE, Selke GW, Kourafalos V, Magnússon E, Einarsdóttir R, Adams R, Joppi R, Allocati E, Jakupi A, Viksna A, Greičiūtė-Kuprijanov I, Vella Bonanno P, Suttorp V, Melien Ø, Plisko R, Mardare I, Meshkov D, Novakovic T, Fürst J, Zara C, Marković-Peković V, Grubiša N, Befrits G, Puckett R, Vulto AG. Moorkens E, et al. Among authors: viksna a. Front Pharmacol. 2021 Jan 8;11:591134. doi: 10.3389/fphar.2020.591134. eCollection 2020. Front Pharmacol. 2021. PMID: 33519450 Free PMC article.
Identification of Factors Determining Patterns of Serum C-Reactive Protein Level Reduction in Response to Treatment Initiation in Patients with Drug-Susceptible Pulmonary Tuberculosis.
Kivrane A, Ulanova V, Grinberga S, Sevostjanovs E, Viksna A, Ozere I, Bogdanova I, Simanovica I, Norvaisa I, Pahirko L, Bandere D, Ranka R. Kivrane A, et al. Among authors: viksna a. Antibiotics (Basel). 2024 Dec 14;13(12):1216. doi: 10.3390/antibiotics13121216. Antibiotics (Basel). 2024. PMID: 39766606 Free PMC article.
Discordance Between Phenotypic and WGS-Based Drug Susceptibility Testing Results for Some Anti-Tuberculosis Drugs: A Snapshot Study of Paired Mycobacterium tuberculosis Isolates with Small Genetic Distance.
Sadovska D, Nodieva A, Pole I, Vīksna A, Ķimsis J, Ozere I, Norvaiša I, Bogdanova I, Bandere D, Ranka R. Sadovska D, et al. Among authors: viksna a. Infect Drug Resist. 2024 Aug 1;17:3289-3307. doi: 10.2147/IDR.S468997. eCollection 2024. Infect Drug Resist. 2024. PMID: 39108991 Free PMC article.
Unraveling tuberculosis patient cluster transmission chains: integrating WGS-based network with clinical and epidemiological insights.
Sadovska D, Ozere I, Pole I, Ķimsis J, Vaivode A, Vīksna A, Norvaiša I, Bogdanova I, Ulanova V, Čapligina V, Bandere D, Ranka R. Sadovska D, et al. Among authors: viksna a. Front Public Health. 2024 May 20;12:1378426. doi: 10.3389/fpubh.2024.1378426. eCollection 2024. Front Public Health. 2024. PMID: 38832230 Free PMC article.
Effect of NAT2, GSTM1 and CYP2E1 genetic polymorphisms on plasma concentration of isoniazid and its metabolites in patients with tuberculosis, and the assessment of exposure-response relationships.
Ulanova V, Kivrane A, Viksna A, Pahirko L, Freimane L, Sadovska D, Ozere I, Cirule A, Sevostjanovs E, Grinberga S, Bandere D, Ranka R. Ulanova V, et al. Among authors: viksna a. Front Pharmacol. 2024 Mar 22;15:1332752. doi: 10.3389/fphar.2024.1332752. eCollection 2024. Front Pharmacol. 2024. PMID: 38584604 Free PMC article.
Exploring Variability in Rifampicin Plasma Exposure and Development of Anti-Tuberculosis Drug-Induced Liver Injury among Patients with Pulmonary Tuberculosis from the Pharmacogenetic Perspective.
Kivrane A, Ulanova V, Grinberga S, Sevostjanovs E, Viksna A, Ozere I, Bogdanova I, Zolovs M, Ranka R. Kivrane A, et al. Among authors: viksna a. Pharmaceutics. 2024 Mar 12;16(3):388. doi: 10.3390/pharmaceutics16030388. Pharmaceutics. 2024. PMID: 38543282 Free PMC article.
61 results